CHU Bretonneau

Tours 9 trials 4 recruiting

9 Registered trials

4 Currently recruiting

Organisation

CHU Bretonneau

Location

Tours, France

Identifier

ORL-000001424

Address

2 boulevard Tonnelé, 37044, France

Departments

Hématologie
Hematology and cell therapy
Medical oncology
Neurology
oncologie
Oncologue

Clinical trials at this site (9)

Search interface

Evaluation study of a treatement with Nivolumab and Ipilimumab or tKi according to molecular group in naïve metastatic Kidney cancer Pending

2024-520045-23-00 Kidney cancer 4
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06)) Recruiting

2023-505040-19-00 Non-seminomatous germ-cell tumors (including testis, re 4 2023-04-11
MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex… Recruiting

2024-514139-50-00 Multiple myeloma 5 2022-11-14
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel… Ended

2024-518244-20-01 Urothelial Carcinoma 4 2022-04-25
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety … Halted

2024-516671-33-00 Amyotrophic Lateral Sclerosis 5 2021-05-24
Study comparing the standard administration of immunotherapy (IO) versus the same agent administered each three months in patients with loca… Ended

2024-513707-14-00 Only patients with oncologic locally advanced or metast 5 2022-01-14